Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5352857 | 0.83 | ALDH1A1 (0.31) | ALDH1A1MAPK1KDM4ENPC1GAA | |
| SCHEMBL5360384 | 0.80 | ALDH1A1 (0.38) | ALDH1A1MAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL5361215 | 0.76 | ALDH1A1 (0.36) | ALDH1A1LMNASMN1; SMN2KDM4E | |
| SCHEMBL3756942 | 0.71 | ALDH1A1 (0.39) | ALDH1A1MAPK1LMNASMN1; SMN2KDM4E | |
| Hydrochloric Acid SCHEMBL5351087 | 0.70 | ALDH1A1 (0.41) | ALDH1A1MAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL31435555 | 0.67 | ALDH1A1 (0.44) | ALDH1A1MAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL5353878 | 0.64 | MEN1 (0.31) | NPC1 | |
| SCHEMBL3765154 | 0.64 | ALDH1A1 (0.62) | ALDH1A1MAPK1LMNASMN1; SMN2KDM4E | |
| SCHEMBL11760449 | 0.61 | GSK3B (0.34) | — | |
| SCHEMBL5357813 | 0.60 | NPSR1 (0.31) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217723-B2 | Substituted benzothiophenes, e.g., 7Z)-7-hydroxyimino-4,5,6,7-tetrahydro-benzo[b]thiophene-3-sulfonic acid [2-(4-fluorophenyl)-2-hydroxyethyl]-methyl-amide; treating allergies such as atopic dermatitis, allergic coryza, bronchial asthma, hypersensitive pneumoniac and pulmonary aspergillosis. | EISAI CO., LTD. (JP) | 2007-05-15 | — | — | US | disclosed |
| US-20050227959-A1 | Heterocyclic compound having oxime group | EISAI CO., LTD. (JP) | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227959-A1 | Heterocyclic compound having oxime group | STAT6, HRH4, HRH2 | ALDH1A1 1391/4885MAPK1 755/4885LMNA 4744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.